

# Elisa Giovannetti

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6015903/elisa-giovannetti-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

302  
papers

12,654  
citations

50  
h-index

104  
g-index

361  
ext. papers

15,069  
ext. citations

6  
avg, IF

6.24  
L-index

#	Paper	IF	Citations
302	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
301	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. <i>Cancer Research</i> , <b>2010</b> , 70, 4528-38	10.1	361
300	Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 725-737	8.7	295
299	Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. <i>Cancer Research</i> , <b>2006</b> , 66, 3928-35	10.1	276
298	Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. <i>PLoS ONE</i> , <b>2010</b> , 5, e10630	3.7	230
297	Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1797-803	12.9	170
296	Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 110-8	4.3	163
295	Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 1599-612	8.3	152
294	Platinum-induced neurotoxicity and preventive strategies: past, present, and future. <i>Oncologist</i> , <b>2015</b> , 20, 411-32	5.7	151
293	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , <b>2017</b> , 32, 238-252.e9	24.3	150
292	Analysis of drug interactions. <i>Methods in Molecular Biology</i> , <b>2011</b> , 731, 421-34	1.4	141
291	Tyrosine kinase inhibitors: Multi-targeted or single-targeted?. <i>World Journal of Clinical Oncology</i> , <b>2011</b> , 2, 80-93	2.5	131
290	Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. <i>Molecular Pharmacology</i> , <b>2008</b> , 73, 1290-300	4.3	130
289	MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. <i>Gastroenterology</i> , <b>2014</b> , 146, 268-77.e18	13.3	125
288	Drug resistance in pancreatic cancer: Impact of altered energy metabolism. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 114, 139-152	7	123
287	Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 81, 103-22	7	117
286	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 37269-80	3.3	112

285	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 172-82	8.7	99
284	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 1-12	3.5	99
283	c-Met as a Target for Personalized Therapy. <i>Translational Oncogenomics</i> , <b>2015</b> , 7, 13-31		90
282	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1493-500	5.9	81
281	Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2936-43	12.9	81
280	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1389-404	7.5	80
279	Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2581-90	12.9	78
278	A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3078-87	12.9	77
277	Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 161, 154-178	6.8	77
276	USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. <i>Molecular Cancer</i> , <b>2013</b> , 12, 91	42.1	76
275	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1605-12	10.3	74
274	Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1735-46	6.1	73
273	Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2010</b> , 878, 1059-68	3.2	73
272	The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. <i>Annals of Oncology</i> , <b>2013</b> , 24, 734-41	10.3	72
271	Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 1387-95	6.1	72
270	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. <i>Oncotarget</i> , <b>2018</b> , 9, 19006-19013	3.3	71
269	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , <b>2017</b> , 995, 97-125	3.6	69
268	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , <b>2019</b> , 46, 100644	23.2	67

267	Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. <i>Cancer Research</i> , <b>2013</b> , 73, 6745-56	10.1	65
266	TGF- $\beta$ induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. <i>Nature Communications</i> , <b>2018</b> , 9, 1845	17.4	61
265	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 990-1004	14.4	60
264	Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. <i>Seminars in Cancer Biology</i> , <b>2017</b> , 44, 43-59	12.7	59
263	Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 581-93	6.1	59
262	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 159-70	2.6	58
261	High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e49145	3.7	57
260	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 89, 300-13	7	56
259	Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 35-40	8.7	55
258	N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. <i>European Journal of Medicinal Chemistry</i> , <b>2011</b> , 46, 5398-407	6.8	54
257	HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2019</b> , 56, 533-566	9.4	53
256	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 6987-7005	5.6	52
255	Thiazoles, Their Benzofused Systems, and Thiazolidinone Derivatives: Versatile and Promising Tools to Combat Antibiotic Resistance. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 7923-7956	8.3	50
254	Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2008</b> , 27, 720-5	1.4	50
253	Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 769-75	8.7	50
252	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 9	22.4	48
251	miRNAs: micro-managers of anticancer combination therapies. <i>Angiogenesis</i> , <b>2017</b> , 20, 269-285	10.6	47
250	Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7099-107	12.9	47

249	Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. <i>Journal of Medicinal Chemistry</i> , <b>2001</b> , 44, 3994-4000	8.3	47
248	Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. <i>Current Pharmaceutical Biotechnology</i> , <b>2014</b> , 15, 475-85	2.6	47
247	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 940-950	3.3	46
246	miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2014</b> , 33, 384-93	1.4	45
245	MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. <i>Drug Resistance Updates</i> , <b>2019</b> , 42, 1-11	23.2	43
244	Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 207-11	14.4	42
243	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S37	4.0	41
242	Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 750-9	8.7	40
241	Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/βcatenin signalling in pancreatic adenocarcinoma. <i>Oncotarget</i> , <b>2014</b> , 5, 5335-49	3.3	40
240	Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. <i>Seminars in Cancer Biology</i> , <b>2017</b> , 44, 153-169	12.7	39
239	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt346	9.7	39
238	Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 2811-29	3.3	39
237	Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1964-73	6.1	38
236	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 670-677	10.3	38
235	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , <b>2010</b> , 10, 511	4.8	38
234	Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. <i>Leukemia Research</i> , <b>2008</b> , 32, 19-24	2.7	38
233	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1423-328.9		38
232	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 289-97	8.7	37

231	Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm-Associated Infections. <i>ChemMedChem</i> , <b>2021</b> , 16, 65-80	3.7	37
230	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. <i>Scientific Reports</i> , <b>2017</b> , 7, 44686	4.9	36
229	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1641-52	2.6	36
228	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , <b>2019</b> , 11,	6.6	35
227	Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. <i>BioMed Research International</i> , <b>2014</b> , 2014, 678401	3	35
226	Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 395-6	8.9	35
225	Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 69-80	2.6	35
224	Role of Akt signaling in resistance to DNA-targeted therapy. <i>World Journal of Clinical Oncology</i> , <b>2016</b> , 7, 352-369	2.5	35
223	Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	33
222	Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation. <i>Scientific Reports</i> , <b>2017</b> , 7, 16623	4.9	33
221	The role of alternative splicing in cancer: From oncogenesis to drug resistance. <i>Drug Resistance Updates</i> , <b>2020</b> , 53, 100728	23.2	33
220	Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , <b>2020</b> , 189, 112088 <sup>6,8</sup>		32
219	MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2013</b> , 18, 851-60	5.4	32
218	miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1343-1358	2.6	32
217	Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. <i>Lung Cancer</i> , <b>2012</b> , 78, 92-9	5.9	32
216	Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 1542-53	8.7	32
215	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. <i>Drug Resistance Updates</i> , <b>2017</b> , 31, 43-51	23.2	31
214	Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. <i>PLoS ONE</i> , <b>2013</b> , 8, e78656	3.7	31

213	Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2725-2732	10.3	29
212	Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. <i>Cellular Oncology (Dordrecht)</i> , <b>2019</b> , 42, 261-273	7.2	29
211	Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. <i>Seminars in Cancer Biology</i> , <b>2015</b> , 35, 11-9	12.7	29
210	Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1120-7	8.7	29
209	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. <i>Laboratory Investigation</i> , <b>2008</b> , 88, 773-84	5.9	29
208	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1553-9	10.3	29
207	2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 167, 200-210	6.8	29
206	Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2011</b> , 30, 1214-22	1.4	28
205	New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?. <i>Oncotargets and Therapy</i> , <b>2016</b> , 9, 6065-6074	4.4	28
204	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 147-57	3.5	27
203	A microRNA meta-signature for pancreatic ductal adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 267-71	3.8	27
202	Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 927-939	3.3	27
201	NF- $\kappa$ B drives acquired resistance to a novel mutant-selective EGFR inhibitor. <i>Oncotarget</i> , <b>2015</b> , 6, 42717-33	3.3	27
200	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. <i>EBioMedicine</i> , <b>2019</b> , 39, 215-225	8.8	27
199	Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1073-86	2.6	26
198	Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 1712-20	7.5	26
197	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 60, 238-248	12.7	26
196	Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. <i>Nature Communications</i> , <b>2021</b> , 12, 1270	17.4	25

195	Thymidylate synthase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1343-56	5.9	24
194	Pharmacogenomics in non-small-cell lung cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , <b>2009</b> , 61, 408-17	18.5	24
193	Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. <i>Pharmacological Research</i> , <b>2007</b> , 55, 343-9	10.2	24
192	Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 681-9	8.7	24
191	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 818-832	3.3	23
190	Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 655-64	6.1	23
189	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 781-98	3.8	23
188	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , <b>2020</b> , 271, 1137-1147	7.8	23
187	1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 209, 112892	6.8	23
186	3-(6-Phenylimidazo [2,1-][1,3,4]thiadiazol-2-yl)-1-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Molecules</i> , <b>2020</b> , 25,	4.8	22
185	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919841233	5.4	21
184	Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2015</b> , 15, 1525-9	3.8	21
183	Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e221-2; author reply e223-5	2.2	21
182	Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. <i>Current Topics in Medicinal Chemistry</i> , <b>2012</b> , 12, 1649-59	3	21
181	On the pharmacogenetics of non-small cell lung cancer treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 307-17	5.5	20
180	Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1016-22	7.5	20
179	Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2011</b> , 11, 695-701	3.8	20
178	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 940-50	3.3	20



177	Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 435-42	2.3	20
176	On the use of pharmacogenetics in cancer treatment and clinical trials. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2532-43	7.5	19
175	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 2047-2063	4.4	19
174	AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. <i>PLoS ONE</i> , <b>2014</b> , 9, e108057	3.7	19
173	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 524-33	12.9	19
172	The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib. <i>Current Drug Targets</i> , <b>2014</b> , 15, 1322-30	3	19
171	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , <b>2020</b> , 25, e634-e643	5.7	18
170	The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 567-582	5.9	18
169	Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 4535-4541	4.4	18
168	The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 385-92	5.9	18
167	Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 6020-6032	4.3	18
166	Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF- $\kappa$ B signaling pathways. <i>Life Sciences</i> , <b>2020</b> , 249, 117470	6.8	17
165	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 72, 21-44	7	17
164	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 547-58	3.5	17
163	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	17
162	Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with $^3\text{Odeoxy-}^3\text{C}[\text{H}]\text{fluorothymidine}$ positron emission tomography. <i>PLoS ONE</i> , <b>2013</b> , 8, e63705	3.7	17
161	The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. <i>Expert Review of Molecular Diagnostics</i> , <b>2018</b> , 18, 1005-1009	3.8	17
160	Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1- $\text{b}$ ][1,3,4]thiadiazol-2-yl)-1-indole Derivatives Against Pancreatic Cancer Cells. <i>Anticancer Research</i> , <b>2019</b> , 39, 3615-3620	2.3	16

159	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 129	7.7	16
158	Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 1189-94	4.9	16
157	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , <b>2010</b> , 10, 180-90	3.5	16
156	Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR. <i>Oncotarget</i> , <b>2016</b> , 7, 5240-57	3.3	16
155	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. <i>Oncotarget</i> , <b>2016</b> , 7, 28556-69	3.3	16
154	Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. <i>Current Drug Targets</i> , <b>2014</b> , 15, 1331-40	3	16
153	Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. <i>Anticancer Research</i> , <b>2014</b> , 34, 517-23	2.3	16
152	Pharmacogenetics of treatments for pancreatic cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 437-447	5.5	15
151	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 644-656	8.7	15
150	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. <i>Future Oncology</i> , <b>2012</b> , 8, 1015-29	3.6	15
149	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , <b>2017</b> , 8, 53068-53083	3.3	15
148	New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 170	5.3	14
147	Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2014</b> , 33, 403-12 <sup>4</sup>	1.4	14
146	Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1026-36	6.1	14
145	MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 975-89	4.3	14
144	Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	14
143	Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 140, 8-16	7	13
142	The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13

141	Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 417-30	2.3	13
140	Genetic variation: effect on prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 446-56	11.2	13
139	Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). <i>Current Drug Targets</i> , <b>2010</b> , 11, 12-28	3	13
138	Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2009</b> , 8, 146-54	3.8	13
137	The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer. <i>Anticancer Research</i> , <b>2020</b> , 40, 4807-4818	2.3	13
136	RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 311-322	5.9	12
135	Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. <i>Neoplasia</i> , <b>2013</b> , 15, 61-72	6.4	12
134	Ceramide analogues in apoptosis: a new strategy for anticancer drug development. <i>Il Farmaco</i> , <b>2003</b> , 58, 205-11		12
133	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 1081-1090	3.8	12
132	1,2,4-Oxadiazole Toposentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3 $\beta$ Kinase. <i>ChemMedChem</i> , <b>2021</b> , 16, 537-554	3.7	12
131	GSK3 $\beta$ as a novel promising target to overcome chemoresistance in pancreatic cancer. <i>Drug Resistance Updates</i> , <b>2021</b> , 58, 100779	23.2	12
130	Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 818-32	3.3	12
129	Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 927-39	3.3	12
128	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
127	Loss of heterozygosity status of D9S105 marker is associated with downregulation of Kr $\mu$ pel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. <i>Pancreatology</i> , <b>2011</b> , 11, 30-42	3.8	11
126	Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2010</b> , 29, 419-26	1.4	11
125	Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 160, 103234	7	11
124	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4569-75	12.9	10

123	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. <i>Oncology Letters</i> , <b>2013</b> , 6, 1487-1491	2.6	10
122	New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1560-1561	10.3	10
121	Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. <i>Cellular Oncology (Dordrecht)</i> , <b>2020</b> , 43, 1147-1159	7.2	10
120	Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,	12.7	10
119	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , <b>2019</b> , 166, 128-138	6	9
118	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
117	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , <b>2018</b> , 52, 259-268	12.7	9
116	The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1395, 163-87	1.4	9
115	Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. <i>Expert Review of Molecular Diagnostics</i> , <b>2013</b> , 13, 325-9	3.8	9
114	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 609-18	2.6	9
113	TFAP2E-DKK4 and chemoresistance in colorectal cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 966; author reply 966	59.2	9
112	Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncogenesis</i> , <b>2013</b> , 18, 317-26	1.3	9
111	Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 91	12.8	9
110	Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1287-1298	4	9
109	Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 209, 112857	6.8	9
108	Tumor grafted - chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 947-968	5.5	9
107	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1326-1331	8.7	9
106	Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). <i>Cancers</i> , <b>2021</b> , 13,	6.6	9

105	A New Oxadiazole-Based Toposentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.. <i>Molecules</i> , <b>2021</b> , 27,	4.8	9
104	Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 35-41	4.9	8
103	Gender, cytidine deaminase, and 5-aza/decitabine--letter. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3105	12.9	8
102	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. <i>Annals of Oncology</i> , <b>2011</b> , 22, 482-4	10.3	8
101	Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 461-471	3.5	7
100	Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. <i>Frontiers in Bioscience - Landmark</i> , <b>2011</b> , 16, 116-30	2.8	7
99	DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. <i>Current Drug Metabolism</i> , <b>2011</b> , 12, 956-65	3.5	7
98	Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2010</b> , 29, 408-13	1.4	7
97	"The only thing I know is that I know nothing": 5-fluorouracil in human milk. <i>Annals of Oncology</i> , <b>2012</b> , 23, 543-4	10.3	7
96	Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2008</b> , 27, 787-93	1.4	7
95	In vitro studies on gemcitabine combinations with other antiproliferatives. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 5, v17-19	10.3	7
94	Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas. <i>Cancers</i> , <b>2020</b> , 13,	6.6	7
93	"Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
92	Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. <i>Experimental Hematology and Oncology</i> , <b>2020</b> , 9, 18	7.8	7
91	Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 733-6	3.8	7
90	A synthetic lethal bullet. <i>Nature Nanotechnology</i> , <b>2018</b> , 13, 6-7	28.7	7
89	Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
88	Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 1155-1162	3.8	6

87	To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. <i>Anticancer Research</i> , <b>2019</b> , 39, 3303-3309	2.3	6
86	Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2011</b> , 30, 1203-13	1.4	6
85	5'-Nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 16437-16450	3.3	6
84	A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2016</b> , 35, 643-651	1.4	6
83	CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. <i>Molecules</i> , <b>2019</b> , 24,	4.8	6
82	The role of the microbiome in drug resistance in gastrointestinal cancers. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 165-176	3.5	6
81	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. <i>Journal of Cellular Physiology</i> , <b>2020</b> , 235, 8085-8097	7	5
80	Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). <i>Annals of Oncology</i> , <b>2019</b> , 30, v931-v932 <sup>10.3</sup>	10.3	5
79	CYB5A and autophagy-mediated cell death in pancreatic cancer. <i>Autophagy</i> , <b>2014</b> , 10, 697-8	10.2	5
78	Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 768-73	8.9	5
77	Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , <b>2018</b> ,	4.5	5
76	Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 166, 103454	7	5
75	Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. <i>Anticancer Research</i> , <b>2019</b> , 39, 3609-3614	2.3	4
74	SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3623-4.9	4.9	4
73	Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2008</b> , 27, 740-5	1.4	4
72	The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S27-30	8.9	4
71	Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , <b>2016</b> , 7, 425-432	2.5	4
70	New Imidazo[2,1-][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. <i>Anticancer Research</i> , <b>2020</b> , 40, 4913-4919	2.3	4

69	New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4.. <i>Molecules</i> , <b>2022</b> , 27,	4.8	4
68	Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1213-1214	3.8	3
67	MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer. <i>Current Pharmacology Reports</i> , <b>2015</b> , 1, 223-233	5.5	3
66	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 39-48	3.5	3
65	hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , <b>2016</b> , 21, e4	5.7	3
64	Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 511-2	2.2	3
63	Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, But do they contradict themselves?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 144, 102824	7	3
62	Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 1033-1036	3.8	3
61	Tivantinib-Gemcitabine: Pharmacological Rational for a New Combination in Pancreatic Cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, iv158	10.3	3
60	Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3341	2.2	3
59	Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1275-8	3.5	3
58	Serum miR-1290 as a marker of pancreatic cancer--letter. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5250-1	12.9	3
57	Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer.. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	3
56	A New Generation of Vaccines in the Age of Immunotherapy. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 137	6.3	3
55	Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3863-74	3.3	3
54	Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles. <i>Gut</i> , <b>2020</b> , 69, 404-405	19.2	3
53	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
52	Breastfeeding during R-CHOP chemotherapy: please abstain!. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 107-111	7.5	2

51	Usefulness of Measuring microRNAs in Bile and Plasma for Pancreatic Ductal Adenocarcinoma Diagnosis. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 768-9	0.7	2
50	Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI. <i>Pteridines</i> , <b>2013</b> , 24, 69-79	0.6	2
49	"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e79-80	8.9	2
48	Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. <i>Il Farmaco</i> , <b>2003</b> , 58, 85-9		2
47	The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periapillary Diseases, a Novel Approach.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
46	Abstract 493: Circulating biliary tract microRNA signature discriminates cholangiocarcinoma from pancreatic cancer <b>2018</b> ,		2
45	Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML. <i>Blood</i> , <b>2014</b> , 124, 924-924	2.2	2
44	Molecular mechanism underlying the pharmacological interactions of the protein kinase C- $\beta$ inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 816-830	4.4	2
43	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.. <i>Communications Biology</i> , <b>2022</b> , 5, 41	6.7	2
42	Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. <i>Oncoscience</i> , <b>2020</b> , 7, 76-80	0.8	2
41	Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S1010-S1013	0.3	2
40	Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4601-4604	3.3	2
39	Abstract 4335: Role of proton-coupled folate transporter expression in resistance of mesothelioma patients treated with pemetrexed <b>2015</b> ,		2
38	The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. <i>Molecules</i> , <b>2019</b> , 24,	4.8	2
37	Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. <i>Gastroenterology</i> , <b>2021</b> , 161, 1758-1763	13.3	2
36	Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway. <i>Cellular Signalling</i> , <b>2021</b> , 85, 110069	4.9	2
35	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 692-693	2.2	1
34	An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. <i>Cancer</i> , <b>2019</b> , 119, 2668-3	6.4	1



33	Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1445-7	2.6	1
32	Differences of gene expression in non-small cell lung cancer: are histology, tumor site, and methodology relevant?. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1310-1; author reply 1311	8.9	1
31	Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. <i>Oncoscience</i> , <b>2020</b> , 7, 76-80	0.8	1
30	A mechanical memory of pancreatic cancer cells		1
29	Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights. <i>Oncologist</i> , <b>2021</b> , 26, e2306-e2307	5.7	1
28	Organotypic-liver slice culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 937-946	5.5	1
27	Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. <i>Epigenetics</i> , <b>2021</b> , 1-24	5.7	1
26	Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 867-868	5.5	1
25	Multidrug-resistant transporter expression does not always result in drug resistance. <i>Cancer Science</i> , <b>2018</b> , 109, 3360-3362	6.9	1
24	A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
23	The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells.. <i>Drug Resistance Updates</i> , <b>2022</b> , 62, 100833	23.2	1
22	Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. <i>Biomolecules</i> , <b>2022</b> , 12, 651	5.9	1
21	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies <b>2019</b> , 25-60		0
20	Thymidylate synthase inhibitors for thoracic tumors. <i>Pteridines</i> , <b>2013</b> , 24, 57-67	0.6	0
19	The effect of lactate dehydrogenase-A inhibition on intracellular nucleotides and mitochondrial respiration in pancreatic cancer cells.. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2022</b> , 1-11	1.4	0
18	The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response-Letter. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4126	12.9	0
17	Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.. <i>Toxicology and Applied Pharmacology</i> , <b>2022</b> , 440, 115951	4.6	0
16	Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma.. <i>Expert Review of Clinical Pharmacology</i> , <b>2022</b> , 1-18	3.8	0

15	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2594	12.9
14	Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers. <i>Current Clinical Pathology</i> , <b>2017</b> , 137-150	0.1
13	Resistance Mechanisms to AZD9291 and Rociletinib-Letter. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3966	12.9
12	Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer). <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 807-807	3.3
11	SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. <b>2021</b> , 4, 904-922	
10	Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 14145-14145	2.2
9	Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24078-e24078	2.2
8	Pharmacology and Clinical Development of New Molecularly Targeted Agents. <i>Current Clinical Pathology</i> , <b>2015</b> , 9-29	0.1
7	The PI3K-Akt signaling leads to synergy of erlotinib and crizotinib in wild-type NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20043-e20043	2.2
6	Evaluation of EZH2 SNPs in cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10611-10611	0.1
5	Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1464-1465	8.7
4	A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 3135-3137	4.9
3	Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-2	3.6
2	Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 520-522	7.5
1	"Depart from evil, and do good": turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 103659	7